Intervacc AB is a Swedish company active in Life Science. To meet the increasing demands of effective vaccines in animal health Intervacc develops new vaccines based on recombinant proteins.

The technology platform is based on research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The focus is primarily on the development of its first vaccine candidate, Strangvac ®, which is a vaccine against strangles caused by Streptococcus equi. Strangvac ® has shown good documented protective effect against a disease that presently lacks an adequate vaccine protection.

Intervacc is now a public company with more than 180 shareholders. The research team along with Nordvacc Läkemedel, Knutsson Holdings and Lyftet Holdings represents the major shareholders.